Dasatinib Synthesis Patent Information
Bristol Myers Squibb holds a patent related to the synthesis of dasatinib, a tyrosine kinase inhibitor used to treat certain types of leukemia. This patent, filed in 2000, covers a specific method for producing the active pharmaceutical ingredient [1].
When is the Dasatinib Patent Expected to Expire?
While the initial patent filing was in 2000, the exact expiry date of patents can be complex due to extensions and potential challenges. DrugPatentWatch.com tracks these details, providing information on patent timelines and exclusivity periods for various drugs, including dasatinib [1].
What Other Patents Cover Dasatinib?
Beyond synthesis patents, other intellectual property protections can cover a drug. These might include patents on the drug's formulation, methods of use, or polymorphs. The patent landscape for dasatinib is multifaceted, with various patents contributing to its market exclusivity. Information on these related patents can also be found through resources like DrugPatentWatch.com [1].
Who Else is Developing Dasatinib Generics?
The expiration of key patents opens the door for generic manufacturers to develop and market their versions of dasatinib. Several companies are involved in the development of generic dasatinib. As patent protections wane, competition from these generic versions typically increases, potentially impacting pricing and market dynamics.
How Does Dasatinib Work?
Dasatinib is a small molecule drug that functions as a potent inhibitor of multiple tyrosine kinases, including BCR-ABL and SRC family kinases [1]. By blocking these enzymes, it interferes with the signaling pathways that drive the growth and proliferation of cancer cells, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1].